External validation of yonsei nomogram predicting chronic kidney disease development after partial nephrectomy: An international, multicenter study
Raheem A, Landi I, Alowidah I, Capitanio U, Montorsi F, Larcher A, Derweesh I, Ghali F, Mottrie A, Mazzone E, De Naeyer G, Campi R, Sessa F, Carini M, Minervini A, Raman J, Rjepaj C, Kriegmair M, Autorino R, Veccia A, Mir M, Claps F, Choi Y, Ham W, Santok G, Tadifa J, Syling J, Furlan M, Simeone C, Bada M, Celia A, Carrión D, Bazan A, Ruiz C, Malki M, Barber N, Hussain M, Micali S, Puliatti S, Ghaith A, Hagras A, Ghoneem A, Eissa A, Alqahtani A, Rumaih A, Alwahabi A, Alenzi M, Pavan N, Traunero F, Antonelli A, Porcaro A, Illiano E, Costantini E, Rha K. External validation of yonsei nomogram predicting chronic kidney disease development after partial nephrectomy: An international, multicenter study. International Journal Of Urology 2022, 30: 308-317. PMID: 36478459, DOI: 10.1111/iju.15108.Peer-Reviewed Original ResearchConceptsNew-onset CKDCKD stageChronic kidney disease developmentExternal validationCKD stage ICT1 renal massesKidney disease developmentPreoperative eGFRPatient ageConsecutive patientsMulticenter studyTumor sizePartial nephrectomyRenal massesProgression rateGood calibration propertiesStage IProgression probabilityPatientsNomogramIndividual riskCKDDisease developmentEGFRMedian valueDoes presence of diabetes mellitus impact patient oncological outcomes in renal cell carcinoma: A multicenter analysis.
Saidian A, Walia A, Patil D, Saito K, Patel D, Nguyen M, Chakoumakos M, Ghali F, Narasimhan R, Perry J, Meagher M, Yasuda Y, Fujii Y, Master V. Does presence of diabetes mellitus impact patient oncological outcomes in renal cell carcinoma: A multicenter analysis. Journal Of Clinical Oncology 2022, 40: 325-325. DOI: 10.1200/jco.2022.40.6_suppl.325.Peer-Reviewed Original ResearchRenal cell carcinomaProgression-free survivalKaplan-Meier analysisCancer-specific survivalIndependent risk factorMultivariable analysisDiabetes mellitusRisk factorsOverall survivalCell carcinomaStage ICox regression multivariable analysisImpact of DMPatients' oncological outcomesNon-diabetic patientsRegression multivariable analysisOncologic effectCause mortalityOncological outcomesDiabetic patientsMulticenter analysisMeier analysisMale sexRCC patientsStage subgroupsDisparities in Cancer Specific and Overall Survival Outcomes in African Americans With Renal Cell Carcinoma: Analysis From the International Marker Consortium for Renal Cancer (INMARC)
Meagher M, Patil D, Saito K, Javier-Desloges J, Bradshaw A, Patel S, Cotta B, Yasuda Y, Eldefrawy A, Ghali F, Nasseri R, Wan F, Fujii Y, Master V, Derweesh I. Disparities in Cancer Specific and Overall Survival Outcomes in African Americans With Renal Cell Carcinoma: Analysis From the International Marker Consortium for Renal Cancer (INMARC). Urology 2022, 163: 164-176. PMID: 34995562, DOI: 10.1016/j.urology.2021.12.022.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaCancer-specific mortalityCancer-specific survivalKaplan-Meier analysisCause mortalityOverall survivalMultivariable analysisSurvival outcomesCell carcinomaStage IIIStage IFive-year cancer-specific survivalAfrican AmericansNon-African American patientsRenal cancer databasePapillary renal cell carcinomaOverall survival outcomesAfrican American raceStage III/IV RCCHigher stageIndolent histologiesSecondary outcomesPrimary outcomeRadical nephrectomyPositive margins